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Abstract
Background: The metabolic syndrome (MetS) is a clustering of interrelated risk factors which doubles the risk of
cardio-vascular disease (CVD) in 5–10 years and increases the risk of type 2 diabetes 5 fold. The identification of
modifiable CVD risk factors and predictors of MetS in an otherwise healthy population is necessary in order to
identify individuals who may benefit from early interventions. We sought to determine the prevalence of MetS as
defined by the harmonized criteria and its predictors in subjectively healthy black Africans from various urban
centres in Kenya.
Method: We used data collected from healthy black Africans in Kenya as part of a global study on establishing
reference intervals for common laboratory tests. We determined the prevalence of MetS and its components using
the 2009 harmonized criterion. Receiver operator characteristic (ROC) curve analysis was used to determine the area
under the curves (AUC) for various predictors of MetS. Youden index was used to determine optimum cut-offs for
quantitative measurements such as waist circumference (WC).
Results: A total of 528 participants were included in the analysis. The prevalence of MetS was 25.6% (95% CI: 22.
0%–29.5%). Among the surrogate markers of visceral adiposity, lipid accumulation product was the best predictor of
MetS with an AUC of 0.880 while triglyceride was the best predictor among the lipid parameters with an AUC of
0.816 for all participants. The optimal WC cut-off for diagnosing MetS was 94 cm and 86 cm respectively for males
and females.
Conclusions: The prevalence of MetS was high for a healthy population highlighting the fact that one can be
physically healthy but have metabolic derangements indicative of an increased CVD risk. This is likely to result in an
increase in the cases of CVD and type 2 diabetes in Kenya if interventions are not put in place to reverse this trend.
We have also demonstrated the inappropriateness of the WC cut-off of 80 cm for black African women in Kenya
when defining MetS and recommend adoption of 86 cm.
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Background
The non-communicable disease (NCD) burden is
expected to increase globally by 17% and by 27% in the
African region in the next 10 years. NCDs are projected
to overtake communicable diseases as the major cause
of morbidity in sub Saharan Africa by the year 2030 [1].
Smoking, hypertension, abdominal obesity, diabetes mel-
litus and elevated Apolipoprotein B/A-1 ratio have been
shown to account for up to 90% of the risk for a first
myocardial infarction in Africa according to the INTER-
HEART study [2]. Unfortunately, the prevalence of these
risk factors continues to increase as urbanization takes
root in the African continent [3].
The metabolic syndrome (MetS) is a clustering of in-
terrelated risk factors which doubles the risk of cardio-
vascular disease (CVD) in 5–10 years and increases the
risk of type 2 diabetes 5 fold [4]. The identification of
modifiable CVD risk factors and predictors of MetS in
an otherwise healthy population is necessary in order to
identify individuals who may benefit from early interven-
tions. It has been shown that subjectively healthy indi-
viduals may have biochemical abnormalities in keeping
with the presence of MetS [5]. A study carried out in the
US showed that 23.5% of normal-weight adults were
metabolically abnormal and conversely, 51.3% of over-
weight adults and 31.7% of obese adults were metabolic-
ally healthy [6]. Metabolic derangements may be an
early indicator of increased CVD risk even in normal
weight or subjectively healthy individuals. Initial results
of reference interval (RI) studies carried out in Japan,
China, Turkey, Saudi Arabia and USA have shown that
the levels of fasting plasma glucose (FPG), triglycerides
(TGs), alanine aminotransferase (ALT) and gamma-
glutamyl transferase (GGT) increase while high density
lipoprotein cholesterol (HDL-C) decreases as body mass
index (BMI) increases. This pattern of reduced HDL-C,
increased TG and FPG suggests the presence of MetS in
some of the reference individuals recruited despite ad-
herence to a strict inclusion criteria designed to exclude
unhealthy individuals. This has raised the question
whether RIs should be further stratified according to
BMI for those analytes where it is a major source of
variation [7].
Whereas increasing levels of waist circumference (WC)
and BMI have been associated with increased CVD risk,
there is a continuous search for robust predictors of MetS.
Both BMI and WC do not distinguish between visceral
adipose tissue (VAT) and subcutaneous adipose tissue
(SAT). VAT plays a significant role in the pathogenesis of
CVD due to its association with insulin resistance and in-
creased levels of VAT has been associated with increased
cardio-metabolic risk and coronary artery calcification re-
gardless of BMI [8, 9]. One of the emerging surrogate
markers of visceral adiposity and predictor of MetS yet to
be extensively studied in a black African population is the
lipid accumulation product (LAP), a parameter whose cal-
culation is based on WC and serum TG levels [10]. LAP
has been shown to have a strong association with the
presence of MetS in healthy adults, an accurate predictor
of MetS in those aged 50 years and above, as well as an as-
sociation with diabetes in studies carried out in Europe
and Asia [11–14].
Visceral adiposity index (VAI) is another emerging
parameter that indirectly expresses visceral fat function
and has been found to be independently associated with
coronary heart disease, myocardial infarction, transient
ischemic attack and ischemic stroke. The calculation of
VAI is based on WC, BMI, triglycerides, and HDL chol-
esterol and hence includes both physical and metabolic
parameters [15]. In China, VAI was shown to be posi-
tively associated with type 2 diabetes and was a better
predictor of diabetes than BMI, WC and waist to height
ratio [16]. VAI was derived from an Italian cohort largely
comprising of Caucasians and hence needs validation in
a black African population.
Hypertriglyceridaemia and low HDL-C are the only
lipid parameters included in the harmonized MetS cri-
terion [4]. There is controversy as to the specific role el-
evated TGs play in atherogenesis. Whereas increased
TGs have been associated with increased risk of CVD, it
is thought that they are a surrogate marker for choles-
terol remnants which play a direct role in atheromatous
plaque formation [17]. Varbo et al. demonstrated in a
Danish population that non-fasting cholesterol remnants
are a risk factor for ischaemic heart disease independent
of HDL-C levels with an increase of 1 mmol/L associ-
ated with a 2.8 fold increase in risk [18]. The utility of
cholesterol remnants in determination of CVD risk or
MetS in healthy black Africans is unknown.
The prevalence of MetS in any population is influenced
by many factors including the specific criteria adopted to
define it. For example, in a rural population in Ghana, the
overall prevalence of MetS defined by the International
Diabetic Federation (IDF) and the National Cholesterol
Education Programme Adult Treatment Panel III (ATP
III) criteria was 35.9% and 15.0% respectively [19]. In
2009, a harmonized criterion for diagnosing MetS was de-
veloped whose components included abdominal obesity,
dyslipidemia, hyperglycemia, and hypertension [4]. Using
the harmonized definition, the prevalence of MetS in an
urban population in Kenya was reported as 34.6% with the
prevalence being significantly higher in women at 40.2%.
However, this study was only limited to one constituency
in the capital city of Nairobi which limits the
generalizability of the results despite the use of random
sampling when identifying participants [20]. Furthermore,
this study didn’t explore the utility of LAP and VAI as pre-
dictors of MetS in a black African population.
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We sought to determine the prevalence of MetS as de-
fined by the harmonized criteria in subjectively healthy
black Africans from various urban centres in Kenya. We
also determined the ability of various lipid parameters,
LAP, VAI, WC and BMI to predict the presence of MetS.
Methods
We used data from 533 healthy black Africans partici-
pating in a global RI study in Kenya. This study is part
of an initiative by the Committee of Reference Intervals
and Decision Limits (C-RIDL) under the auspices of the
International Federation of Clinical Chemistry (IFCC).
Kenya is one of 3 participating countries in Africa, the
other ones being Nigeria and South Africa. Majority of
recruited participants in Kenya were urban dwellers
from the capital city Nairobi and its environs, Kisii
County in the western part of Kenya and Nakuru town
based in the Great Rift valley. Recruitment was mainly
done by seeking adult volunteers aged 18–65 years of
age through use of posters in public areas including
churches, universities, colleges, hospitals and companies.
Social media and word of mouth were also used. This
was done between January and October 2015 and
written informed consent was sought from each par-
ticipant after giving a written and verbal explanation
of the study.
Inclusion criteria
Inclusion was limited to healthy adults 18–65 years of
age and was stratified into 4 age groups: 18–29, 30–39,
40–49 and 50–65 years with a similar distribution of
males and females in each age strata.
Exclusion criteria
Exclusion criteria included participants with a BMI
greater than 35 kg/m2, consumption of ethanol greater
than or equal to 70 g per day [equivalent to 5 alcoholic
drinks], smoking more than 20 tobacco cigarettes per
day, taking regular medication for a chronic disease (dia-
betes mellitus, hypertension, hyperlipidemia, allergic dis-
orders, depression), recent (less than 15 days) recovery
from acute illness, injury or surgery requiring
hospitalization, known carrier state of hepatitis B, hepa-
titis C or human Immunodeficiency virus, pregnant or
within one year after childbirth. Individuals with any
chronic disease were excluded except for the age group
50–65 years where those with well controlled hyperten-
sion were recruited. Towards the end of the study, a few
individuals with a BMI greater than 35 kg/m2 but less
than 40 kg/m2 were recruited due to difficulties in
recruiting healthy participants in the older age groups.
The exclusion criteria were defined in the questionnaire
filled by the participants and those who were excluded
didn’t have blood samples taken.
Measurements
All participants had measurements of blood pressure
(BP), WC and body mass index (BMI) taken. A single
measurement of BP was performed in a sitting position
after at least 15 min of rest using a calibrated OMRON
M3 automated BP monitor (Omron Healthcare, Kyoto,
Japan) that uses an upper arm cuff. A repeat BP meas-
urement was done if the initial reading was consistent
with hypertension. If the initial and second reading were
in agreement then the first reading was adopted. If there
was a discrepancy in terms of BP status then a third
reading was done as a tie breaker. WC was measured
using a tape measure over light clothing at the level of
the umbilical cord to ensure a consistent reference point
while BMI was automatically calculated after measuring
the participants’ height and weight using a Seca 703
weighing scale digital column with height meter scale
(Seca, Hamburg, Germany). On average, measuring WC
over light clothing increased the measurement by ap-
proximately 1 cm which was subsequently deducted.
Height was measured after removal of shoes to the near-
est 0.5 cm, WC to the nearest 1 cm and weight to the
nearest 0.1 kg after removal of shoes and bulky clothing.
Sample handling
All participant samples were collected after obtaining in-
formed consent and filling of a questionnaire. All partici-
pants had an overnight fast as per the study protocol.
Samples were collected and centrifuged within 4 h after
collection and stored at −80°c until shipment on dry ice
to the reference laboratory in South Africa. All the sam-
ple analysis for the biochemistries and immunoassays
were performed at the Pathcare reference laboratory in
Cape Town, South Africa which is an International
Organization for Standardization (ISO) 15189 accredited
laboratory. Thawing was only done once before sample
analysis. As part of the RI study, all participating labora-
tories used a common panel of sera with assigned values
to ensure accuracy of reported results and alignment of
values if any biases were identified. All the listed tests in
Table 1 were carried out on a Beckman Coulter AU5800.
The analytical methods for the various tests are shown
in Table 1.
MetS diagnosis
The 2009 harmonized definition was used to diagnose
MetS which requires the presence of any 3 of the follow-
ing: increased WC (men: ≥ 94 cm, women: ≥ 80 cm),
low HDL-C (men: <40 mg/dl (1 mmol/l), women:
<50 mg/dl (1.3 mmol/l)), hypertriglyceredimia ≥150 mg/dl
(1.7 mmol/l), elevated BP (systolic BP ≥ 130 mmHg and/
or diastolic ≥85 mmHg or drug treatment for hyperten-
sion) and elevated blood sugar (FPG ≥ 100 mg/dl
(5.6 mmol/l) or diabetes mellitus [4].
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CVD risk calculation
The 10 year CVD risk was calculated using the Framing-
ham risk calculation [21]. Family history of CVD was
not included as this information wasn’t captured in the
study questionnaire.
LAP calculation
LAP was calculated as (WC [cm] − 65) × (TG [mmol/
L]) for males, and (WC [cm] − 58) × (TG [mmol/L]) for
females [10].
VAI calculation
VAI was calculated as (WC[cm]/(39.68 + (1.88 x BMI))) x
(TG/1.03) x (1.31/HDL-C [mmol/L]) for males and
(WC[cm]/(36.58 + (1.89 x BMI))) x (TG/0.81) x (1.52/
HDL-C [mmol/L]) for females [15].
Non HDL-C
Non HDL-C was calculated as fasting total cholesterol
minus HDL-C.
Cholesterol remnants
Cholesterol remnants were calculated as fasting total
cholesterol minus HDL-C minus LDL-C.
Statistical analysis
The prevalence of MetS was presented as a percentage
with 95% confidence intervals (CI). Descriptive statistics
for continuous variables were presented as medians with
interquartile ranges (IQRs). The Mann Whitney U test
was used to compare the distribution pattern of continu-
ous variables between males and females and those with
and without MetS. Where the distribution patterns were
similar, medians were compared using the independent
samples median test. Mean ranks were compared where
the distribution patterns were not similar. Binary logistic
regression was used to determine the association be-
tween cardio-metabolic risk factors and MetS presence.
Adjusted odds ratios (ORs) were subsequently deter-
mined in a model that excluded the MetS components.
For hs-CRP, uric acid and GGT, the median value was
used as a cut-off to classify individuals as having in-
creased or normal levels. Binary logistic regression was
also used to determine the strength of association be-
tween MetS and CVD risk. Chi-square was used to com-
pare cardio-metabolic risk factors between male and
female participants as well as between individuals with a
BMI < 25 kg/m2 and those with BMIs ≥25 kg/m2. A p-
value < 0.05 was considered statistically significant. Re-
ceiver operator characteristic (ROC) curves were created
and area under the curve (AUC) determined in order to
compare lipid parameters, LAP, VAI, WC and BMI as
predictors of MetS. An AUC ≥ 0.90 was considered ex-
cellent; 0.80–0.90, good; 0.70–0.80, fair; and 0.70–0.50,
poor test performance. The Youden’s index was calcu-
lated and used to determine the cut-offs that gave the
best combination of sensitivity and specificity. Statistical
analysis was carried out using IBM SPSS Statistics for
Windows, Version 20.0 (Armonk, NY: IBM Corp).
Results
A total of 533 participants met the inclusion criteria and
subsequently had samples collected and analysed. How-
ever, 5 participants didn’t have FPG results due to sam-
ple insufficiency and were excluded from this analysis
leaving 528 participants, 255 (48.3%) males and 273
(51.7%) females. BMI was higher in female participants
while WC and BP were higher in males. The difference
in total cholesterol (TC) between male and female par-
ticipants was not statistically significant but TGs were
significantly higher in males and HDL-C lower in fe-
males. FPG levels and liver enzymes were higher in male
participants as shown in Table 2. Only 2 (0.7%) women
were smokers compared to 13 (5.1%) men, a difference
that was statistically significant (p = 0.003).
The overall prevalence of MetS was 25.6% (95% CI:
22.0%–29.5%). The prevalence increased with increase in
age and BMI. The most prevalent component of the
MetS was increased WC which was present in 294
(55.7%) participants while the least prevalent was ele-
vated FPG which was found in 83 (15.7%) participants.
Having GGT or UA values above the median more than
doubled the odds of having MetS as shown in Table 3.
Only 2 out of 135 (1.5%) participants with MetS were
Table 1 List of tests, methodologies and coefficient of variation
Test Method Between run CV
UA Enzymatic colour 0.1%
TC Enzymatic colour calibrated to
CDC Reference Method
(Abell-Kendall)
0.3%
LDL-C Enzymatic colour calibrated to
US CDC
0.4%
TGs Enzymatic colour 0.4%
HDL-C Enzymatic colour calibrated to
US CDC
0.3%
Glucose Enzymatic UV test (hexokinase
method)
0.1%
hsCRP Immuno-turbidimetric 0.8%
ALP Kinetic colour IFCC 0.1%
ALT Kinetic UV IFCC 0.8%
AST Kinetic UV IFCC 0.4%
GGT Kinetic colour IFCC 0.4%
Abbreviations ALP Alkaline phosphatase, ALT Alanine aminotransferase, AST
Aspartate aminotransferase, CDC Centre of Disease Control, CV Coefficient of
variation, GGT Gama glutamyl transferase, HDL-C High density lipoprotein
cholesterol, hsCRP Highly sensitive C-reactive protein, IFCC International
Federation of Clinical Chemistry, LDL-C Low density lipoprotein cholesterol,
TGs Triglycerides, UA Uric acid, US United States
Omuse et al. BMC Endocrine Disorders  (2017) 17:37 Page 4 of 11
smokers compared to 13 out of 393 (3.3%) with no MetS
(p = 0.375). Those who consumed alcohol were 26.7%
(36/135) and 34.6% (136/393) for those with and without
MetS respectively (p = 0.110). A comparison of ALT
(U = 17,197.0, p = 0.000), AST (U = 22,805.0, p = 0.015)
and ALP (U = 21,887.5, p = 0.002) mean ranks in partic-
ipants with and without Mets found that they were all
higher in those with MetS.
The prevalence of MetS was higher in females
though the difference was not statistically significant.
There was a statistically significant difference in the
prevalence of each component of the MetS when
comparing male and female participants except for
FPG. The commonest component of the MetS that
was present in male participants was elevated BP
(53.3%) while in females it was increased WC (71.8%).
No female participant had a 10 year CVD risk >10%
based on their Framingham risk score compared to
10.6% of males as shown in Table 4.
The prevalence of each component of the MetS was
significantly higher in those with a BMI greater ≥25 kg/
m2 compared to those with a BMI < 25 kg/m2 as shown
in Table 5.
ROC curve analysis of LAP, VAI, WC and BMI ability to
predict the presence of MetS showed LAP as having the
highest AUC at 0.880. When male and female data were
analysed separately, the AUC for the 4 parameters were
higher in males with WC, LAP and VAI having excellent
AUCs.With the exception of VAI, all other optimum cut-
offs were lower in females as shown in Table 6. Using a
WC cut-off of 86 cm reduced the prevalence of MetS in
female participants from 26.0% to 23.4%.
The lipid parameter that best predictedMetS was TG
with AUCs of 0.816, 0.887 and 0.770 for all participants,
male and female participants respectively. Measured
LDL-C (mLDL-C) was consistently better than calcu-
lated LDL-C (cLDL-C) at predicting MetS. Non-HDL-C
and cholesterol remnants performed better in males
compared to females as shown in Table 7.
Discussion
The prevalence of MetS of 25.6% found in this study is
quite high given the strict inclusion and exclusion cri-
teria used for the RI study. This sample was meant to be
representative of a healthy black African population in
Kenya and as such the percentage of individuals with
Table 2 Descriptive characteristics of participants
Male (n = 255) Female (n = 273) Total (n = 528) Male vs Female
Median (IQR) Min-Max Median (IQR) Min-Max Median (IQR) Min-Max p-value
Age (years) 38 (19) 20–65 39 (21) 18–64 39 (20) 18–65 0.986*
BMI (kg/m2) 24.87 (5.66) 16.29–34.94 26.10 (6.25) 17.10–38.05 25.46 (5.96) 16.29–38.05 0.000†
LAP 29.52 (40.95) 0.00–388.87 23.97 (29.69) 3.30–205.54 26.94 (35.96) 0.00–388.87 0.055*
VAI 1.51 (1.45) 0.26–21.66 1.35 (1.13) 0.42–20.42 1.43 (1.22) 0.26–21.66 0.163*
WC (cm) 90 (15) 65–124 86 (16) 64–115 89 (17) 64–124 0.000†
SBP (mmHg) 127 (18) 94–167 118 (20) 77–194 123.5 (20) 77–194 0.000†
DBP (mmHg) 81 (12) 56–101 79 (14) 57–112 80 (14) 56–112 0.003†
FPG (mmol/L) 4.9 (0.8) 3.0–15.6 4.8 (0.7) 3.3–19.5 4.9 (0.8) 3.0–19.5 0.022†
TC (mmol/L) 4.7 (1.2) 2.3–8.2 4.6 (1.2) 2.6–7.7 4.6 (1.1) 2.3–8.2 0.732*
HDL-C (mmol/L) 1.1 (0.3) 0.5–2.0 1.2 (0.3) 0.3–2.4 1.1 (0.3) 0.3–2.4 0.000†
cLDL-C (mmol/L) 2.9 (1.1) 1.0–5.8 2.9 (1.0) 1.1–5.4 2.9 (1.0) 1.0–5.8 0.650*
mLDL-C (mmol/L) 2.9 (1.1) 0.9–5.8 2.8 (1.0) 1.3–5.2 2.8 (1.1) 0.9–5.8 0.141*
TG (mmol/L) 1.2 (0.90) 0.32–10.51 0.9 (0.61) 0.33–4.78 1.05 (0.75) 0.32–10.51 0.000†
UA (mmol/L) 0.35 (0.10) 0.18–0.64 0.27 (0.08) 0.13–0.47 0.31 (0.11) 0.13–0.64 0.000†
ALP (U/L) 86 (35) 34–179 84 (38) 31–191 85 (37) 31–191 0.497*
ALT (U/L) 21 (14) 8–96 14 (9) 6–123 18 (11) 6–123 0.000†
AST (U/L 25 (8) 14–73 21 (6) 11–102 23 (7) 11–102 0.000†
GGT (U/L) 31 (24) 9–701 21 (12) 7–211 25 (19) 7–701 0.000†
hsCRP (mg/L) 0.99 (2.05) 0.20–36.25 1.65 (3.19) 0.20–60.75 1.31 (2.63) 0.20–60.80 0.000†
Abbreviations ALP Alkaline phosphatase, ALT Alanine aminotransferase, AST Aspartate aminotransferase, BMI Body Mass Index, BP Blood pressure, CVD
Cardiovascular disease, DBP Diastolic blood pressure, F Female, FPG Fasting plasma glucose, GGT Gama glutamyl transferase, HDL-C High density lipoprotein
cholesterol, hsCRP Highly sensitive C-reactive protein, LAP Lipid accumulation product, cLDL-C calculated low density lipoprotein cholesterol, mLDL-C measured
low density lipoprotein cholesterol, M-Male SBP-Systolic blood pressure, TGs Triglycerides, VAI Visceral adiposity index, UA Uric acid, WC Waist circumference
*comparison of medians
†comparison of mean ranks
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MetS was expected to be much lower. Several studies
have reported the prevalence of MetS in Africa. These
studies are quite heterogeneous by way of individuals in-
cluded and MetS definitions used hence limiting direct
comparisons. Ogbera reported a MetS prevalence of 86%
using the 2009 harmonized definition in diabetic pa-
tients in Lagos, Nigeria [22]. This high prevalence in a
diabetic population is expected given the known associ-
ation between MetS and increased risk of developing
type 2 diabetes [23]. In Ethiopia, Tran et al. reported a
prevalence of 12.5% and 17.9% using the ATP III and
IDF definitions respectively in a presumably healthy
population comprising working class individuals in
Addis Ababa [24]. This prevalence is much lower than
what we have found in our study. Of, note is that the
prevalence of overweight and obese individuals was
lower in the Ethiopian population which we hypothesize
may be attributed to genetic and/or environmental dif-
ferences. Kaduka et al. reported a prevalence of 34.6% in
an urban population in Nairobi, Kenya. This study was
however limited to one constituency in Nairobi hence
limiting the generalizability of the findings. The inclu-
sion criteria was also not as strict as what we used in
our study and this could partly explain the higher re-
ported prevalence [20].
The most prevalent component of the MetS was in-
creased WC which was present in 294 (55.7%) partici-
pants followed by elevated BP found in 241 (45.6%) of
study participants. This is consistent with what has been
found in other studies carried out in sub-Saharan Africa
(SSA) [20, 24]. However, the most common MetS com-
ponent in males was hypertension (53.3%) and increased
Table 3 Association between cardio-metabolic risk factors and metabolic syndrome
Variable Categories Number Metabolic syndrome status Univariate bMultivariate
Present-No. (%) Absent-No. (%) p-value Crude OR
(95% CI)
p-value Adjusted OR
(95% CI)
Gender Malea 255 64 (25.1%) 191 (74.9%)
Female 273 71 (26.0%) 202 (74.0%) 0.811 1.05 (0.71–1.55) 0.523 1.20 (0.68–2.13)
Age (years) 18-29a 134 6 (4.5%) 128 (95.5%)
30–39 136 23 (16.9%) 113 (83.1%) 0.002 4.34 (1.71–11.04) 0.051 2.64 (1.00–6.99)
40–49 131 45 (34.4%) 86 (65.6%) 0.000 11.16 (4.56–27.31) 0.000 6.06 (2.35–15.60)
50–65 127 61 (48.0%) 66 (52.0%) 0.000 19.72 (8.10–48.00) 0.000 11.74 (4.61–29.88)
BMI (kg/m2) <25.00a 242 19 (7.9%) 223 (92.1%)
25.00–29.99 198 76 (38.4%) 122 (61.6%) 0.000 7.31 (4.22–12.66) 0.000 5.08 (2.80–9.22)
30.00–39.99 88 40 (45.5%) 48 (54.5%) 0.000 9.78 (5.22–18.34) 0.000 5.23 (2.57–10.66)
WC (cm) <94 (M) OR <80 (F)a 234 4 (1.7%) 230 (98.3%)
≥94 (M) OR ≥80 (F) 294 131 (44.6%) 163 (55.4%) 0.000 46.21 (16.75–127.50)
TGs (mmol/L) <1.7a 437 63 (14.4%) 374 (85.6%)
≥1.7 91 72 (79.1%) 19 (20.9%) 0.000 22.50 (12.70–39.85)
HDL-C (mmol/L) ≥1(M) OR ≥1.3 (F)a 304 38 (12.5%) 266 (87.5%)
<1(M) OR <1.3 (F) 224 97 (43.3%) 127 (56.7%) 0.000 5.35 (3.48–8.22)
BP (mmHg) SBP < 130 OR DBP < 85a 287 21 (7.3%) 266 (92.7%)
SBP ≥ 130 OR DBP ≥ 85 241 114 (47.3%) 127 (52.7%) 0.000 11.37 (6.82–18.96)
FPG (mmol/L) <5.6a 445 65 (14.6%) 380 (85.4%)
≥5.6 83 70 (84.3%) 13 (15.7%) 0.000 31.48 (16.47–60.16)
hsCRP (mg/L) <1.3a 262 44 (16.8%) 218 (83.2%)
≥1.3 266 91 (34.2%) 175 (65.8%) 0.000 2.58 (1.71–3.89) 0.620 1.14 (0.686–1.880)
GGT (IU/L) <25a 263 45 (17.1%) 218 (82.9%)
≥25 265 90 (34.0%) 175 (66.0%) 0.000 2.491 (1.654–3.752) 0.003 2.173 (1.295–3.648)
UA (mmol/L) <0.31a 252 47 (18.7%) 205 (18.3%)
≥0.31 276 88 (31.9%) 188 (68.1%) 0.000 2.042 (1.361–3.063) 0.000 2.042 (1.361–3.063)
Abbreviations BMI Body Mass Index, BP Blood pressure, CI Confidence interval, CVD Cardiovascular disease, DBP Diastolic BP, F Female, FPG Fasting plasma glucose,
GGT Gamma-glutamyl transferase, HDL-C High density lipoprotein cholesterol, hs CRP highly sensitive C-reactive protein, M Male, SBP Systolic BP, TGs Triglycerides,
UA uric acid, WC Waist circumference
aIndicates reference category,
bComponents of MetS excluded in the multivariate analysis
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WC (71.8%) in females. In South Africa, HDL-
C < 1.3 mmol/L was found to be the most prevalent of
the MetS components in black African women at 70.1%
closely followed by increased WC at 69.3% compared to
54.2% and 71.8% for low HDL-C and increased WC re-
spectively in our study [25]. WC is a measure of both
VAT and SAT. Increased visceral adiposity contributes to
the insulin resistance that is central in the pathogenesis
of MetS and is associated with the production of adipo-
cytokines which contribute to the chronic low grade in-
flammation seen in MetS. WC was a better predictor of
MetS than BMI in our study but had a lower AUC than
both LAP and VAI. Chen et al. found that VAI was bet-
ter than BMI and WC in predicting the presence of dia-
betes in a Chinese cohort [16]. Gender specific ROC
curve analysis in our study showed that WC was a better
predictor of MetS in males than in females and was su-
perior to VAI. A WC greater than 93.5 cm in male par-
ticipants had a sensitivity of 95.7%, specificity of 80.6%
and AUC of 0.913 which is excellent for a simple meas-
urement that can be carried out in any clinical setting. It
is interesting that the optimum WC cut-off of 93.5 cm is
similar to the proposed European cut-off for abdominal
obesity of 94 cm that is used in the MetS 2009 harmo-
nized criterion for men. The women cut-off of 85.5 cm
is much higher than the European cut-off of 80 cm
highlighting the need to adopt population specific cut-
offs [4]. The use of the 80 cm cut-off in black African
women may be misclassifying many of them as having
abdominal obesity. A study carried out in Johannesburg,
Table 4 Gender comparison of metabolic syndrome component prevalence
Variable Categories Male (n = 255) No. (%) Female (n = 273) No. (%) p-value
BMI (kg/m2) <25.00 132 (51.8%) 110 (40.3%) 0.001
25.00–29.99 95 (37.3%) 103 (37.7%)
30.00–39.99 28 (11.0%) 60 (22.0%)
WC (cm) <94 (M) OR <80 (F) 157 (61.6%) 77 (28.2%) 0.000
≥94 (M) OR ≥80 (F) 98 (38.4%) 196 (71.8%)
TGs (mmol/L) <1.7 194 (76.1%) 243 (89.0%) 0.000
≥1.7 61 (23.9%) 30 (11.0%)
HDL-C (mmol/L) ≥1(M) OR ≥1.3 (F) 179 (70.2%) 125 (45.8%) 0.000
<1(M) OR <1.3 (F) 76 (29.8%) 148 (54.2%)
BP (mmHg) SBP < 130 OR DBP < 85 119 (46.7%) 168 (61.5%) 0.001
SBP ≥ 130 OR DBP ≥ 85 136 (53.3%) 105 (38.5%)
FPG (mmol/L) <5.6 212 (83.1%) 233 (85.3%) 0.486
≥5.6 43 (16.9%) 40 (14.7%)
10 year CVD risk (%) ≤10% 228 (89.4%) 273 (100.0%) 0.000
>10% 27 (10.6%) 0 (0.0%)
Abbreviations BMI Body Mass Index, BP Blood pressure, CVD Cardiovascular disease, DBP Diastolic BP, FPG Fasting plasma glucose, F Female, HDL-C High density
lipoprotein cholesterol, M Male, SBP Systolic BP, TGs Triglycerides, WC Waist circumference
Table 5 Comparison of metabolic syndrome component prevalence in different BMI categories
Variable Categories BMI < 25.00 (n = 242) No. (%) BMI ≥ 25.00 (n = 286) No. (%) p-value
WC (cm) <94 (M) OR <80 (F) 188 (77.7%) 46 (16.1%) 0.000
≥94 (M) OR ≥80 (F) 54 (22.3%) 240 (83.9%)
TGs (mmol/L) <1.7 223 (92.1%) 214 (74.8%) 0.000
≥1.7 19 (7.9%) 72 (25.2%)
HDL-C (mmol/L) ≥1(M) OR ≥1.3 (F) 157 (64.9%) 147 (51.4%) 0.002
<1(M) OR <1.3 (F) 85 (35.1%) 139 (48.6%)
BP (mmHg) SBP < 130 OR DBP < 85 152 (62.8%) 135 (47.2%) 0.000
SBP ≥ 130 OR DBP ≥ 85 90 (37.2%) 151 (52.8%)
FPG (mmol/L) <5.6 230 (95.0%) 215 (75.2%) 0.000
≥5.6 12 (5.0%) 71 (24.8%)
Abbreviations BMI Body Mass Index, BP Blood pressure, DBP Diastolic BP, FPG Fasting plasma glucose, F Female, HDL-C High density lipoprotein cholesterol, M
Male, SBP Systolic BP, TGs Triglycerides, WC Waist circumference
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South Africa derived an optimal cut-off to diagnose
MetS in urban black African women of 91.5 cm. The
prevalence of MetS in this population was 42.1% and the
WC was measured at the smallest girth above the umbil-
icus [25]. This suggests that the optimal cut-off would
have been higher if measured at the level of the
umbilicus like we did in our study. Further longitudinal
studies are required to validate the WC cut-offs we have
proposed and assess their ability to predict CVD risk in
a black African population.
Elevated GGT and UA levels independently more than
doubled the odds of having MetS. Surprisingly, elevated
Table 6 Summary of ROC curve and Youden Index analysis for BMI, WC, VAI and LAP as predictors of MetS
Gender Variable AUC (95% CI) YI Cut-off Sensitivity Specificity
Males & Females BMI 0.766 (0.725–0.808) 0.457 26.23 0.770 0.687
WC 0.825 (0.789–0.862) 0.518 89.5 0.867 0.651
VAI 0.858 (0.818–0.897) 0.599 2.057 0.726 0.873
LAP 0.880 (0.846–0.914) 0.591 37.205 0.815 0.776
Males BMI 0.841 (0.789–0.892) 0.587 25.71 0.859 0.728
WC 0.913 (0.879–0.947) 0.759 93.5 0.957 0.806
VAI 0.905 (0.859–0.951) 0.697 1.727 0.922 0.775
LAP 0.949 (0.923–0.976) 0.749 42.895 0.843 0.749
Females BMI 0.702 (0.638–0.765) 0.363 24.99 0.873 0.49
WC 0.766 (0.710–0.821) 0.453 85.5 0.859 0.594
VAI 0.814 (0.752–0.876) 0.529 2.065 0.648 0.881
LAP 0.822 (0.764–0.879) 0.502 30.56 0.775 0.728
Abbreviations AUC Area under the curve, BMI Body mass index, CI Confidence intervals, LAP Lipid accumulation product, WC Waist circumference, VAI Visceral
adiposity index, YI Youden Index
Table 7 ROC curve analysis for lipid parameters as predictors of MetS
Gender Variable AUC (95% CI) YI Cut-off Sensitivity Specificity
Males & Females TG 0.816 (0.769–0.862) 0.517 1.27 0.726 0.791
HDL-C 0.721 (0.669–0.774) 0.318 1.1 0.756 0.562
mLDL-C 0.660 (0.605–0.714) 0.268 3.0 0.652 0.616
cLDL-C 0.578 (0.520–0.636) 0.146 3.2 0.459 0.687
TC 0.648 (0.592–0.704) 0.258 5.0 0.548 0.710
non HDL-C 0.706 (0.654–0.759) 0.342 3.4 0.785 0.557
CholRem 0.751 (0.701–0.801) 0.421 0.7 0.622 0.799
Males TG 0.887 (0.841–0.933) 0.645 1.68 0.734 0.911
HDL-C 0.722 (0.642–0.803) 0.395 0.9 0.594 0.801
mLDL-C 0.719 (0.650–0.789) 0.346 2.8 0.828 0.518
cLDL-C 0.613 (0.532–0.693) 0.190 2.8 0.703 0.487
TC 0.731 (0.660–0.802) 0.358 4.9 0.688 0.670
non HDL-C 0.778 (0.714–0.843) 0.456 3.5 0.891 0.565
CholRem 0.814 (0.748–0.879) 0.551 0.7 0.813 0.738
Females TG 0.770 (0.697–0.843) 0.471 1.25 0.620 0.851
HDL-C 0.752 (0.684–0.820) 0.412 1.1 0.704 0.708
mLDL-C 0.605 (0.525–0.685) 0.214 3.1 0.521 0.693
cLDL-C 0.547 (0.464–0.629) 0.123 3.5 0.296 0.827
TC 0.572 (0.490–0.654) 0.173 5.0 0.465 0.708
non HDL-C 0.645 (0.567–0.722) 0.264 3.4 0.690 0.574
CholRem 0.712 (0.642–0.782) 0.307 0.7 0.451 0.856
Abbreviations AUC Area under the curve, CholRem Cholesterol remnants, cLDL-C calculated LDL cholesterol, CI Confidence intervals, mLDL-C measured LDL
cholesterol, non HCL-C non HDL cholesterol, TC Total cholesterol, TG Triglycerides, YI Youden Index
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hsCRP did not independently increase the odds of one
having MetS. Elevated GGT is known to occur in non-
alcoholic fatty liver disease (NAFLD) which represents the
hepatic component of MetS and its increase may be a
physiological response to the increased oxidation stress
seen in MetS as GGT plays a role in the metabolism of
glutathione which is an important anti-oxidant [26]. Mat-
sha et al. demonstrated that increasing levels of GGT were
associated with increasing levels of insulin resistance as
well as an increase in the number of components of MetS
present in a mixed ancestry population in South Africa.
This was so even in GGT levels within the reference inter-
val. However, additional tests of liver enzymes were not
performed in this study to enable inferences on the patho-
physiology behind the increase of GGT in MetS [27]. In
our study, elevated GGT was associated with an increase
in ALT, AST and ALP suggesting that MetS may be asso-
ciated with mild hepatitis and cholestasis. It is known that
hepatocyte injury does occur in individuals with NAFLD,
however, canalicular cholestasis is more common in alco-
holic liver disease [28].
Despite the difference in prevalence of Mets in male
and female participants not being statistically significant,
the 10 year CVD risk was significantly higher in male
participants with 10.6% having a greater than 10% risk
compared to 0% among females. This suggests that the
presence of MetS confers a different CVD risk depend-
ing on gender with the risk being lower in females. We
explored the possibility of over diagnosis of MetS in fe-
male participants given the disparity in WC between the
Caucasian cut-off and the higher values for females re-
ported in studies carried out in Africa including our
study. However, whereas using a WC cut-off of 86 cm
reduced the MetS prevalence in females from 26.0% to
23.4%, the difference compared to males was still not
statistically significant hence this doesn’t explain the ob-
served disparity in CVD risk. This is even more surpris-
ing when you consider that women had a statistically
significant higher level of hsCRP than men. This finding
further adds to the uncertainty surrounding the use of
hsCRP in CVD risk prediction [29]. The optimal cut-off
for TGs that predicted the presence of MetS was
1.27 mmol/L for combined males and females, 1.68 mmol/
L for males and 1.25 mmol/L for females. Given these
findings, we do advocate the adoption of separate TG cut-
offs for males and females for the diagnosis of MetS in a
black African population. The higher TG levels and WC
in men compared to women is in keeping with the known
positive correlation between TG levels and visceral adipos-
ity [30]. The MetS 2009 harmonized criterion uses a cut-
off of 1.7 mmol/L for both males and females which could
under estimate the prevalence of hypertriglyceridae-
mia in female black Africans and by extension MetS.
Using gender specific TG cut-offs in addition to
adjusting the WC cut-off to 86 cm increased the
MetS prevalence in females to 29.7%. The prevalence
in males remained at 25.1% which is not surprising
given the similarities in our male TG and WC cut-
offs to those used in the harmonized criterion [4].
Of the lipid parameters that are not included in the
MetS definition, cholesterol remnants outperformed
non-HDL-C, mLDL-C and cLDL-C in predicting the
presence of MetS. Calculated non-fasting cholesterol
remnant has been shown to be an independent risk fac-
tor for ischaemic heart disease and myocardial infarction
in a Caucasian population [17, 18]. There is a paucity of
data on the utility of cholesterol remnants and non
HDL-C in predicting the presence of MetS in black Afri-
cans. In our study, the lipid parameters were better pre-
dictors in males than in females. Prospective cohort
studies are needed to determine whether cholesterol
remnants are an independent risk factor for CVD in
black Africans.
This study has several limitations. It is a cross sec-
tional study hence causal inferences cannot be made.
The predictive ability of the factors analysed would best
be studied in a longitudinal study and as such, our find-
ings would need to be validated in a prospective cohort
study. However, with a sample size of 528, the study has
sufficient power to draw conclusions on optimal cut-offs
for MetS prediction. We also didn’t collect data on fam-
ily history of CVD and therefore our estimation of CVD
risk based on Framingham calculations may have under-
estimated the 10 year risk. However, it is unlikely that
this omission significantly affected the comparison be-
tween CVD risk in males and females. Our study was
carried out in an urban population hence the findings
cannot be directly extrapolated to a rural population
who are known to have a lower prevalence of obesity
and MetS.
Conclusion
We propose 94 cm and 86 cm as WC cut-offs for males
and females respectively for black Africans in Kenya
when diagnosing MetS. These however need to be vali-
dated prospectively in other countries in SSA. There is
also a need to adopt gender specific MetS TG cut-offs to
avoid over diagnosing hypertriglyceridaemia in black Af-
rican women who have a lower TG level compared to
the 1.7 mmol/L cut-off. The high prevalence of abdom-
inal obesity, hypertension and MetS in our subjectively
healthy population emphasizes the need for primary
healthcare interventions to control the epidemic of CVD
in Kenya. Urbanization in SSA will continue to acceler-
ate the incidence of obesity, diabetes and hypertension
all of which can be avoided or at least reduced by adopt-
ing lifestyle changes such as reduced intake of processed
food that is high in calories and regular exercise to
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ensure a reasonable balance between what is consumed
and what is expended. Unless urgent interventions are
put in place to prevent this epidemic, the additional
morbidity due to CVD will over burden the already
stretched healthcare services in SSA leading to increased
mortality.
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